Quoin Pharmaceuticals Appoints New CFO to Support Commercialization Strategy

Quoin Pharmaceuticals has appointed Sally Lawlor as its new Chief Financial Officer. Lawlor has over 20 years of experience in financial leadership roles and will support the company's commercialization strategy for its lead product candidate, QRX003, in rare and orphan diseases. She replaces Gordon Dunn, who has been thanked for his contributions.

Quoin Pharmaceuticals (NASDAQ: QNRX) has appointed Sally Lawlor as its new Chief Financial Officer (CFO), effective immediately. Lawlor brings over 20 years of financial leadership experience, having most recently served at Sebela Pharmaceuticals and held senior positions at Aptiv Plc and KPMG [1].

The appointment comes as Quoin advances its lead product candidate, QRX003, through pivotal clinical trials for Netherton Syndrome, with full enrollment expected in early to mid-Q1 2026. The company is preparing for a potential New Drug Application (NDA) filing next year and transitioning to a commercial-stage organization [1].

Lawlor will support the company's commercialization strategy for QRX003 and other products in development, including treatments for Peeling Skin Syndrome and other rare dermatologic diseases through a novel topical rapamycin platform. Her extensive experience in commercial-stage finance, global tax strategy, and multinational compliance positions her well to guide Quoin through this critical phase of growth [1].

Dr. Michael Myers, CEO of Quoin Pharmaceuticals, expressed his excitement about the appointment, stating, "As we move closer to completing our QRX003 registrational trials in Netherton Syndrome and prepare for a potential NDA filing next year, we are aligning our leadership structure to support the next phase of Quoin’s growth. We are thrilled to welcome Sally as Chief Financial Officer. She has extensive experience in commercial-stage finance, global tax strategy design and implementation, as well as multinational compliance, which we believe makes her exceptionally qualified to guide Quoin through our transition into a revenue-generating company. Sally adds invaluable expertise to our executive team at this pivotal time. I also want to thank Gordon Dunn for his dedicated contribution during his tenure as Quoin’s CFO. We wish him all the best in his future endeavors" [1].

Quoin Pharmaceuticals is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The company's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas, and others [1].

References:
[1] https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-appoints-new-chief-financial-officer-to-jxxoq9hrdc2c.html